NEW YORK (TheStreet) -- Medtronic's (MDT) $42.9 billion acquisition of Covidien (COV) and the company's proposed incorporation in Ireland will help Medtronic save billions of dollars in taxes that it would have faced if it decided to repatriate about $13 billion of foreign profit the company held overseas.
While the blockbuster deal is a smart way for Medtronic to deal with its foreign cash -- especially given the company's decision to invest $10 billion of cash flow in the U.S. -- it will be a hard deal for tech sector giants like Google (GOOG), Apple (AAPL), Cisco (CSCO), Microsoft (MSFT), Amazon (AMZN), Facebook (FB) and Oracle (ORCL) to replicate. Unfortunately for Silicon Valley, it collectively sits on the biggest stash of undistributed foreign earnings of any sector.
The Medtronic deal for Covidien boils down to the following:
- Over the years, Medtronic has earned billions of dollars of profit in its foreign subsidiaries, many of which are in jurisdictions with lower tax rates than the United States.
- As a result, the company has generally kept its foreign earnings abroad instead of repatriating those profits to the U.S. where they would be taxed at a rate of about 35%.
- That foreign stockpile has helped to keep Medtronic's overall tax rate below the rate that it is charged in the U.S. However, the move also creates liability.
- Were Medtronic to repatriate those funds, it would eventually be taxed at the U.S. rate, meaning undistributed foreign profits present a risk to shareholders.
In buying Ireland-based Covidien, the former health care arm of Tyco (TYC), Medtronic has effectively dealt with any U.S. tax liability it might face from undistributed foreign earnings. Although Medtronic is proposing to take control of Covidien, the company is inverting its ownership for tax purposes and domiciling in Ireland. As a result, it is hard to see the company's foreign profits ever entering U.S. shores or the government's coffers.